MEDS — Trxade Health Income Statement
0.000.00%
- $20.73m
- $17.23m
- $8.27m
- 45
- 59
- 82
- 65
Annual income statement for Trxade Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7.44 | 17.1 | 9.89 | 10.3 | 8.27 |
Cost of Revenue | |||||
Gross Profit | 4.87 | 5.71 | 4.75 | 5.52 | 2.6 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 7.49 | 19.6 | 15.2 | 13.2 | 20.7 |
Operating Profit | -0.053 | -2.51 | -5.29 | -2.92 | -12.4 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.284 | -2.54 | -5.32 | -2.4 | -13.7 |
Net Income After Taxes | -0.284 | -2.54 | -5.32 | -2.4 | -13.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -0.284 | -2.54 | -5.32 | -3.47 | -17.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.284 | -2.54 | -5.32 | -3.47 | -17.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.664 | -3.52 | -7.54 | -1.93 | -11.2 |